N B Leighl

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. doi Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy
    Raymond Ng
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Lung Cancer 61:262-5. 2008
  2. ncbi Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics
    Leora Horn
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Drugs Aging 24:411-28. 2007
  3. ncbi Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, Natio
    Raymond Ng
    Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:2256-61. 2007
  4. pmc Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer
    Kimberly S Chiew
    Department of Medical Oncology and Hematology, Princess Margaret Hospital University Health Network, University of Toronto, ON, Canada
    Health Expect 11:35-45. 2008
  5. ncbi A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer
    Natasha B Leighl
    Department of Medicine, Faculty of Medicine, Princess Margaret Hospital University Health Network, University of Toronto, 5 222 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    Lung Cancer 51:115-21. 2006
  6. doi Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy
    Natasha B Leighl
    Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:2077-84. 2011
  7. ncbi A Phase 2 study of perifosine in advanced or metastatic breast cancer
    Natasha B Leighl
    Medical Oncology, Princess Margaret Hospital University Health Network, Toronto, ON, Canada
    Breast Cancer Res Treat 108:87-92. 2008
  8. doi Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL)
    Natasha B Leighl
    Princess Margaret Hospital, Toronto, Canada
    J Thorac Oncol 5:1970-6. 2010
  9. ncbi Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
    Natasha B Leighl
    Princess Margaret Hospital University of Toronto, Department of Medicine, 5 222 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 52:327-32. 2006
  10. pmc Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 98:1769-73. 2008

Detail Information

Publications41

  1. doi Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy
    Raymond Ng
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Lung Cancer 61:262-5. 2008
    ..Here we explore the outcomes of these agents' uses in clinical practice...
  2. ncbi Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics
    Leora Horn
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Drugs Aging 24:411-28. 2007
    ..The improvements observed in patients' QOL and the cost effectiveness of docetaxel make it a very reasonable choice in older patients with good performance status and advanced disease who are candidates for chemotherapy...
  3. ncbi Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, Natio
    Raymond Ng
    Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:2256-61. 2007
    ..This cost-effectiveness analysis of adjuvant chemotherapy from the perspective of Canada's public health care system was undertaken based on the JBR.10 study population...
  4. pmc Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer
    Kimberly S Chiew
    Department of Medical Oncology and Hematology, Princess Margaret Hospital University Health Network, University of Toronto, ON, Canada
    Health Expect 11:35-45. 2008
    ..We report the development and evaluation of a decision aid (DA) designed to assist patients facing this treatment decision...
  5. ncbi A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer
    Natasha B Leighl
    Department of Medicine, Faculty of Medicine, Princess Margaret Hospital University Health Network, University of Toronto, 5 222 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    Lung Cancer 51:115-21. 2006
    ..We evaluated patient utility through willingness-to-pay (WTP) for these agents in the treatment of advanced NSCLC in Canada...
  6. doi Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy
    Natasha B Leighl
    Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:2077-84. 2011
    ..We examined its impact on patient understanding, treatment decisions, decisional conflict, decision making, consultation satisfaction, anxiety, and quality of life by using a randomized trial design...
  7. ncbi A Phase 2 study of perifosine in advanced or metastatic breast cancer
    Natasha B Leighl
    Medical Oncology, Princess Margaret Hospital University Health Network, Toronto, ON, Canada
    Breast Cancer Res Treat 108:87-92. 2008
    ..Perifosine, an oral alkylphospholipid structurally related to miltefosine, has marked activity against breast cancer cell lines and xenograft models, with broad spectrum cellular effects...
  8. doi Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL)
    Natasha B Leighl
    Princess Margaret Hospital, Toronto, Canada
    J Thorac Oncol 5:1970-6. 2010
    ..A retrospective subgroup analysis was performed to assess the efficacy and safety of bevacizumab-based therapy in elderly patients aged 65 years or older in AVAiL...
  9. ncbi Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
    Natasha B Leighl
    Princess Margaret Hospital University of Toronto, Department of Medicine, 5 222 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 52:327-32. 2006
    ..Response rates for second-line chemotherapy are 15-25%, with a median survival of 5 months. Caelyx, a pegylated liposomal formulation of doxorubicin, may be better tolerated and has activity in SCLC...
  10. pmc Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 98:1769-73. 2008
    ..The DA for advanced NSCLC is feasible, acceptable to patients and improves understanding of advanced NSCLC without increasing patient anxiety...
  11. pmc Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital, 5th Floor Room 105, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 104:413-8. 2011
    ..Thrombotic events necessitating therapeutic anticoagulation (TA) are common in cancer. This report describes the safety of concurrent bevacizumab and TA in three large placebo-controlled clinical studies...
  12. ncbi Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18
    Natasha B Leighl
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada
    J Clin Oncol 23:2831-9. 2005
    ..In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs...
  13. pmc A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
    Natasha B Leighl
    Princess Margaret Hospital Phase 2 Consortium, Ontario, Canada
    J Thorac Oncol 4:1163-9. 2009
    ..This study determined the recommended phase II dose (RP2D) of docetaxel plus GTI-2040, toxicity, and response rate in advanced non-small cell lung cancer (NSCLC)...
  14. ncbi Treatment decision aids in advanced cancer: when the goal is not cure and the answer is not clear
    Natasha B Leighl
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 22:1759-62. 2004
  15. ncbi A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer
    Natasha B Leighl
    Department of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    Clin Lung Cancer 5:107-12. 2003
    ..2 mg/m2 I.V. every 21 days. Antitumor activity was seen at all dose levels. This combination is well tolerated and has evidence of antitumor activity. A phase II evaluation is ongoing...
  16. doi Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials
    Timothy R Asmis
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 26:54-9. 2008
    ..The main objective was to determine if age and/or the burden of chronic medical conditions (comorbidity) are independent predictors of survival, treatment delivery, and toxicity...
  17. doi Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer
    Penelope A Bradbury
    NCIC Clinical Trials Group, Kingston, ON, Canada
    J Natl Cancer Inst 102:298-306. 2010
    ..We undertook an economic analysis of erlotinib treatment in this trial and explored different molecular and clinical predictors of outcome to determine the cost-effectiveness of treating various populations with erlotinib...
  18. doi Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer
    Humberto Lara-Guerra
    University Ave, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 27:6229-36. 2009
    ..Their role in early-stage NSCLC has not been established. Our purpose was to explore the use of preoperative gefitinib in clinical stage I NSCLC to assess tumor response, toxicity, and clinical and molecular predictors of response...
  19. ncbi A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the NCIC CTG JBR.10 trial
    R W Jang
    Princess Margaret Hospital, Toronto, ON, Canada National Cancer Institute of Canada, Kingston, ON, Canada University of Alberta, Edmonton, AB, Canada
    J Clin Oncol 26:6535. 2008
    ..To aid in treatment decision-making, quality-adjusted survival estimates of the JRB.10 trial were derived using a Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) analysis...
  20. doi An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
    A M Horgan
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    Ann Oncol 22:1805-11. 2011
    ..Gefitinib had a better toxicity profile and greater improvements in quality of life (QoL). We undertook a cost-consequence analysis to estimate the direct medical costs of gefitinib compared with docetaxel...
  21. ncbi A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung
    Natasha B Leighl
    Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Canada
    J Thorac Oncol 5:1054-9. 2010
    ..This study evaluated the efficacy and safety of intravenous aflibercept in patients with platinum- and erlotinib-resistant lung adenocarcinoma...
  22. ncbi The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer (NSCLC) chemotherapy trials
    P Wheatley-Price
    Princess Margaret Hospital, Toronto, ON, Canada Queen s University, Kingston, ON, Canada McGill University, Montreal, QC, Canada
    J Clin Oncol 26:8054. 2008
    ..Increased chemotherapy (CT) toxicity has been reported in women with small cell lung-cancer. We investigated the influence of sex on efficacy, toxicity, quality of life (QoL) and dose-delivery in NSCLC...
  23. ncbi Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer
    A M Horgan
    Princess Margaret Hospital, Toronto, ON, Canada
    J Clin Oncol 26:8110. 2008
    ..8110 Background: The INTEREST trial is the first to demonstrate non-inferiority of EGFR TKI gefitinib compared to standard second-line chemotherapy (docetaxel) in NSCLC,with better quality of life in gefitinib-treated patients...
  24. ncbi Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness
    P A Bradbury
    Princess Margaret Hospital, Toronto, ON, Canada Queen s University NCIC Clinical Trials Group, Kingston, ON, Canada Sunnybrook Health Sciences Centre, Toronto, ON, Canada Juravinski Cancer Centre, Hamilton, ON, Canada
    J Clin Oncol 26:6531. 2008
    ..21 trial of erlotinib versus placebo in advanced NSCLC. Here, we investigate the value of combining clinical and molecular predictors of outcome to identify more, and less cost- effective patient subgroups for treatment...
  25. pmc A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, 5 700, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 107:604-11. 2012
    ..To evaluate the safety, pharmacokinetics (PKs), and pharmacodynamics of aflibercept, and to identify the recommended phase II dose (RP2D) of aflibercept in combination with pemetrexed and cisplatin...
  26. ncbi Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer
    Natasha B Leighl
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 20:1344-52. 2002
    ..To determine the cost-effectiveness (CE) of second-line docetaxel compared with best supportive care (BSC) in the TAX 317 trial, a randomized clinical trial of second-line chemotherapy in non-small-cell lung cancer...
  27. pmc Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial
    Raymond W Jang
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 27:4268-73. 2009
    ..To aid in treatment decision making, quality-adjusted survival estimates of the JBR.10 trial were derived using a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis...
  28. ncbi The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC)
    P A Bradbury
    NCIC CTG, Queen s University, Kingston, ON, Canada Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
    J Clin Oncol 27:8075. 2009
    ..We evaluated the validity of this exclusion criterion, by investigating the OS of stage IV NSCLC pts with (BMet) and without (non-BMet) a prior history of BMet recruited to NCIC CTG CTs...
  29. ncbi Diagnostic patterns of non-small cell lung cancer at Princess Margaret Hospital
    M Nadjafi
    University of Toronto, Toronto, ON, Canada University Health Network Toronto General Hospital, Toronto, ON, Canada Department of Biostatistics, University of Toronto, Toronto, ON, Canada University Health Network, Princess Margaret Hospital, and University of Toronto, Toronto, ON, Canada Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    J Clin Oncol 29:e18027. 2011
    ..Hence, histological differentiation of NSCLC is becoming increasingly important in therapeutic decision-making. We reviewed the methods of diagnosing NSCLC at our institution and how often a specific histologic subtype is provided...
  30. ncbi Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group
    A Le Maitre
    National Cancer Institute of Canada, Kingston, ON, Canada National Cancer Institute of Canada, Kingston, ON, Canada University Health Network, Princess Margaret Hospital, Toronto, ON, Canada Margaret and Charles Juravinski Cancer Centre, Hamilton, ON, Canada
    J Clin Oncol 26:8065. 2008
    ..Using data from three lung cancer trials conducted by NCIC CTG we analyzed bleeding in participating patients using LMWH, C or non-steroidal anti-inflammatories (NSAID)...
  31. ncbi Systemic therapy usage and outcomes for patients diagnosed with malignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario, Canada
    A Hasani
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    J Clin Oncol 29:7085. 2011
    ..Since 2005 MPM patients in Ontario have been eligible for ST with pemetrexed/platinum [Workplace Safety Insurance Board (WSIB) coverage] or raltitrexed/platinum (Ontario public healthcare coverage)...
  32. doi Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer
    C Lim
    Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto
    Ann Oncol 26:1415-21. 2015
    ..We assessed the prevalence of biomarker testing for advanced NSCLC patients and whether testing affected the timeliness of treatment decisions...
  33. pmc A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium
    Sara K Taylor
    5 105 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Oncologist 15:810-8. 2010
    ..We evaluated the activity of single-agent pazopanib in recurrent or metastatic breast cancer (MBC)...
  34. doi Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials
    Lisa K Hicks
    Keenan Research Center, Li Ka Shing Knowledge Institute of St Michael s Hospital, Toronto, Ontario, Canada
    Cancer 115:5516-25. 2009
    ..However, to the authors' knowledge, the incidence of VTE in early NSCLC, predictors of VTE, and the prognostic significance of VTE in NSCLC have not been explored...
  35. ncbi Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer
    Antonio L Visbal
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, ON, Canada
    Chest 128:2933-43. 2005
    ..10 trial (5-year survival rate, 15%; risk reduction for recurrence, 40%). Thus, there is compelling evidence to now recommend adjuvant platinum-based combination chemotherapy for patients after resection of early-stage NSCLC...
  36. ncbi A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results
    V Papadimitrakopoulou
    University of Texas M D Anderson Cancer Center, Houston, TX Princess Margaret Hospital, Toronto, ON, Canada Centre Rene Gaudecheau, Saint Herblain Cedex, France Centre Gustave Roussy, Villejuif Cedex, France Sarah Cannon Cancer Center, Nashville, TN Novartis Pharmaceuticals Corportation, Basel, Switzerland Novartis Pharmaceuticals Corporation, East Hanover, NJ Dana Farber Cancer Institute, Boston, MA
    J Clin Oncol 26:8051. 2008
    ..E is an oral epidermal growth factor receptor inhibitor (EGFRI) approved for the treatment of NSCLC pts failing C. Preclinical evidence suggests that R may enhance EGFRI anti-tumor activity and reduce resistance to EGFRI...
  37. ncbi Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL)
    N B Leighl
    Princess Margaret Hospital, Toronto, ON, Canada Charles University, Praha, Czech Republic St Vincentius Kliniken Karlsruhe, Karlsruhe, Germany Regional Centre of Lung Diseases, Poznan, Poland F Hoffmann La Roche, Basel, Switzerland Hospital Grosshansdorf, Grosshansdorf, Germany
    J Clin Oncol 27:8050. 2009
    ..A retrospective analysis was performed to assess the efficacy and safety of Bv plus CG in the subpopulation of elderly pts (≥65 years [yrs])...
  38. doi Initial treatment strategies and outcomes for multifocal bronchioloalveolar carcinoma
    Winson Y Cheung
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario
    Clin Lung Cancer 10:187-92. 2009
    ..Knowledge of current practice patterns and outcomes could help to inform future research...
  39. ncbi Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer
    Farrah Kassam
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Ontario, Canada
    J Thorac Oncol 2:39-43. 2007
    ..This study examines whether referral patterns for adjuvant therapy in NSCLC have changed since the presentation of confirmatory trials...
  40. ncbi Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature
    Giannicola D'Addario
    Kantonsspital St Gallen, Departement Innere Medizin, Fachbereich Onkologie Haematologie, Rorschacherstrasse 95, 9007 St Gallen, Switzerland
    J Clin Oncol 23:2926-36. 2005
    ..This meta-analysis was performed to compare the activity, efficacy and toxicity of platinum-based versus non-platinum-based chemotherapy in patients with advanced non-small-cell lung cancer...
  41. doi Factors contributing to adjuvant therapy decisions
    Kathryn L Howe
    J Thorac Oncol 3:195-6. 2008